243 related articles for article (PubMed ID: 23357047)
1. Myocardial 'no-reflow'--diagnosis, pathophysiology and treatment.
Wong DT; Puri R; Richardson JD; Worthley MI; Worthley SG
Int J Cardiol; 2013 Sep; 167(5):1798-806. PubMed ID: 23357047
[TBL] [Abstract][Full Text] [Related]
2. Myocardial 'no-reflow' prevention.
Magro M; Springeling T; van Geuns RJ; Zijlstra F
Curr Vasc Pharmacol; 2013 Mar; 11(2):263-77. PubMed ID: 23506503
[TBL] [Abstract][Full Text] [Related]
3. [Myocardial no-reflow phenomenon: recent knowledges].
Pontecorvo ML; Spaziani C; Montone RA; Cosentino N; Minelli S; Niccoli G
Recenti Prog Med; 2011 Feb; 102(2):53-7. PubMed ID: 21513120
[TBL] [Abstract][Full Text] [Related]
4. The "no reflow" phenomenon following acute myocardial infarction: mechanisms and treatment options.
Kaul S
J Cardiol; 2014 Aug; 64(2):77-85. PubMed ID: 24799155
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
[TBL] [Abstract][Full Text] [Related]
6. Management of the no-reflow phenomenon.
Butler MJ; Chan W; Taylor AJ; Dart AM; Duffy SJ
Pharmacol Ther; 2011 Oct; 132(1):72-85. PubMed ID: 21664376
[TBL] [Abstract][Full Text] [Related]
7. New strategies for the management of no-reflow after primary percutaneous coronary intervention.
Niccoli G; Cosentino N; Spaziani C; Minelli S; Fracassi F; Crea F
Expert Rev Cardiovasc Ther; 2011 May; 9(5):615-30. PubMed ID: 21615325
[TBL] [Abstract][Full Text] [Related]
8. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction.
Jeong YH; Kim WJ; Park DW; Choi BR; Lee SW; Kim YH; Lee CW; Hong MK; Kim JJ; Park SW; Park SJ
Int J Cardiol; 2010 May; 141(2):175-81. PubMed ID: 19144424
[TBL] [Abstract][Full Text] [Related]
9. [No-reflow: update on diagnosis, pathophysiology and therapeutic strategies].
Montone RA; Camilli M; Del Buono MG; Meucci MC; Gurgoglione F; Russo M; Crea F; Niccoli G
G Ital Cardiol (Rome); 2020 Jun; 21(6 Suppl 1):4S-14S. PubMed ID: 32469339
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal extent of lipid pool assessed by optical coherence tomography predicts microvascular no-reflow after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ikenaga H; Ishihara M; Inoue I; Kawagoe T; Shimatani Y; Miura F; Nakama Y; Dai K; Ohtani T; Ohi K; Miki T; Nakamura M; Kishimoto S; Sumimoto Y; Kihara Y
J Cardiol; 2013 Aug; 62(2):71-6. PubMed ID: 23680004
[TBL] [Abstract][Full Text] [Related]
11. Predicting the no-reflow phenomenon following successful percutaneous coronary intervention.
Galiuto L; Paraggio L; Liuzzo G; de Caterina AR; Crea F
Biomark Med; 2010 Jun; 4(3):403-20. PubMed ID: 20550474
[TBL] [Abstract][Full Text] [Related]
12. Reperfusion injury in acute myocardial infarction: from bench to cath lab. Part II: Clinical issues and therapeutic options.
Monassier JP
Arch Cardiovasc Dis; 2008 Sep; 101(9):565-75. PubMed ID: 19041841
[TBL] [Abstract][Full Text] [Related]
13. Myocardial no-reflow in humans.
Niccoli G; Burzotta F; Galiuto L; Crea F
J Am Coll Cardiol; 2009 Jul; 54(4):281-92. PubMed ID: 19608025
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen".
Bruder O; Breuckmann F; Jensen C; Jochims M; Naber CK; Barkhausen J; Erbel R; Sabin GV;
Herz; 2008 Mar; 33(2):136-42. PubMed ID: 18344033
[TBL] [Abstract][Full Text] [Related]
15. The challenges and impact of microvascular injury in ST-elevation myocardial infarction.
Reinstadler SJ; Stiermaier T; Fuernau G; de Waha S; Desch S; Metzler B; Thiele H; Eitel I
Expert Rev Cardiovasc Ther; 2016; 14(4):431-43. PubMed ID: 26794717
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Wang JW; Chen YD; Wang CH; Yang XC; Zhu XL; Zhou ZQ
Cardiology; 2013; 124(3):153-60. PubMed ID: 23485798
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
Ndrepepa G; Tiroch K; Keta D; Fusaro M; Seyfarth M; Pache J; Mehilli J; Schömig A; Kastrati A
Circ Cardiovasc Interv; 2010 Feb; 3(1):27-33. PubMed ID: 20118156
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.
Jaffe R; Dick A; Strauss BH
JACC Cardiovasc Interv; 2010 Jul; 3(7):695-704. PubMed ID: 20650430
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
Chen WR; Tian F; Chen YD; Wang J; Yang JJ; Wang ZF; Da Wang J; Ning QX
Int J Cardiol; 2016 Apr; 208():109-14. PubMed ID: 26849684
[TBL] [Abstract][Full Text] [Related]
20. No-reflow: incidence and detection in the cath-lab.
Niccoli G; Cosentino N; Spaziani C; Fracassi F; Tarantini G; Crea F
Curr Pharm Des; 2013; 19(25):4564-75. PubMed ID: 23270553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
